Bioinformatics approaches for cross-species liver cancer analysis based on microarray gene expression profiling by Fang, H et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Bioinformatics
Open Access Proceedings
Bioinformatics approaches for cross-species liver cancer analysis 
based on microarray gene expression profiling
HF a n g 1, W Tong*2, R Perkins1, L Shi2, H Hong1, X Cao1, Q Xie1, SH Yim3, 
JM Ward4, HC Pitot5 and YP Dragan2
Address: 1Division of Bioinformatics, Z-Tech Corporation, 3900 NCTR Road, Jefferson, AR 72079, 2Division of Systems Toxicology, National 
Center for Toxicological Research (NCTR), FDA, 3900 NCTR Road, Jefferson, AR 72079, 3Laboratory of Metabolism, Center for Cancer Research, 
National Cancer Institute, NIH, Bethesda, Maryland 20892, 4Verterinary and Tumor Pathology Section, Center for Cancer Research, National 
Cancer Institute, Frederick, Maryland 21702 and 5McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI 53706
Email: H Fang - hfang@nctr.fda.gov; W Tong* - wtong@nctr.fda.gov; R Perkins - rperkins@nctr.fda.gov; L Shi - lshi@nctr.fda.gov; 
H Hong - hhong@nctr.fda.gov; X Cao - xcao@nctr.fda.gov; Q Xie - qxie@nctr.fda.gov; SH Yim - yims@mail.nih.gov; 
JM Ward - jeward@niaid.nih.gov; HC Pitot - pitot@oncology.wisc.edu; YP Dragan - ydragan@nctr.fda.gov
* Corresponding author    
Abstract
Background:  The completion of the sequencing of human, mouse and rat genomes and
knowledge of cross-species gene homologies enables studies of differential gene expression in
animal models. These types of studies have the potential to greatly enhance our understanding of
diseases such as liver cancer in humans. Genes co-expressed across multiple species are most likely
to have conserved functions. We have used various bioinformatics approaches to examine
microarray expression profiles from liver neoplasms that arise in albumin-SV40 transgenic rats to
elucidate genes, chromosome aberrations and pathways that might be associated with human liver
cancer.
Results: In this study, we first identified 2223 differentially expressed genes by comparing gene
expression profiles for two control, two adenoma and two carcinoma samples using an F-test.
These genes were subsequently mapped to the rat chromosomes using a novel visualization tool,
the Chromosome Plot. Using the same plot, we further mapped the significant genes to
orthologous chromosomal locations in human and mouse. Many genes expressed in rat 1q that are
amplified in rat liver cancer map to the human chromosomes 10, 11 and 19 and to the mouse
chromosomes 7, 17 and 19, which have been implicated in studies of human and mouse liver cancer.
Using Comparative Genomics Microarray Analysis (CGMA), we identified regions of potential
aberrations in human. Lastly, a pathway analysis was conducted to predict altered human pathways
based on statistical analysis and extrapolation from the rat data. All of the identified pathways have
been known to be important in the etiology of human liver cancer, including cell cycle control, cell
growth and differentiation, apoptosis, transcriptional regulation, and protein metabolism.
Conclusion: The study demonstrates that the hepatic gene expression profiles from the albumin-
SV40 transgenic rat model revealed genes, pathways and chromosome alterations consistent with
experimental and clinical research in human liver cancer. The bioinformatics tools presented in this
paper are essential for cross species extrapolation and mapping of microarray data, its analysis and
interpretation.
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Background
For decades, classical toxicology has used risk assessments
based on animal studies for regulatory decisions. The
underlying assumption is that important biological func-
tions are often conserved across species. In continuation
of this paradigm, the effort in toxicogenomics is placed on
studying rodents and other surrogates using advanced
genomics technologies, such as DNA microarrays. Micro-
array studies enable simultaneous measurement of the
expression of large numbers of genes. Given the comple-
tion of the DNA sequence of the human, mouse and rat
genomes [1-3], genes identified in microarray studies can
be readily compared across-species with respect to the
gene orthologs [4,5]. This assumes that genes co-
expressed across multiple species are likely to have con-
served functions [6-8]. Thus, microarray analysis offers
the possibility of furthering our understanding of cross-
species commonalities and differences that could lead to
more effective use of animal models to understand the
cause and progression of diseases in human at the mech-
anistic level.
Hepatocellular carcinoma (HCC) is a leading cause of
death worldwide and, like most cancers, is a genetic dis-
ease caused by the accumulation of genetic and epigenetic
cell alterations. The progression of hepatic neoplasia is
characterized by increasing genetic instability, including
duplication and deletion of parts of chromosomes and an
increasing proliferative growth advantage of the affected
cells. Molecular cytogenetic techniques, such as Compar-
ative genomic hybridization (CGH) and Spectral karyo-
typing (SKY) [9-11], have allowed evaluation of
chromosomal aberrations in HCC. More recently, Craw-
ley [12] has demonstrated the ability of comparative
genomic microarray analysis (CGMA) to elucidate altera-
tion of specific genes together with the genetic changes at
the chromosome level based on microarray data. Thus,
microarray analysis provides an unprecedented opportu-
nity to further the understanding of the etiology and pro-
gression of liver cancer.
Bioinformatics methods and tools are essential to analyze
and interpret data from microarrays. The critical and
urgent task is to associate altered patterns of gene expres-
sion with disease. Interpreting microarray data in the con-
text of signaling and regulatory pathways is a particularly
effective bioinformatics approach to transform data into
biological meaning and to generate hypotheses for further
research. Using pathways, disease mechanisms can be
interpreted as disturbances of the intricate interconnec-
tions among genes, molecules and cells. Most reported
pathway analysis of microarray data has examined the
role of differentially expressed genes in pathways selected
with a priori knowledge. Alternatively, significant path-
ways can be identified based on statistical analysis, poten-
tially leading to new discoveries and a more complete
interpretation of microarray data in the context of biolog-
ical processes at the mechanistic level.
The primary mechanism for the analysis of HCC is by the
administration of carcinogenic agents. A number of
model systems have been developed to understand the
pathogenesis of primary liver cancer [13-15]. Addition-
ally, the development of transgenic models permit the
analysis of the genetic basis for the induction and progres-
sion of HCC [16-19]. The albumin-Simian virus 40
(SV40) T antigen transgenic rat contains the mouse albu-
min-promoter/enhancer linked to the coding region of
the SV40 large T antigen (SV 40 tag). SV40 T antigen inac-
tivates both p53 and Rb, resulting in spontaneous devel-
opment of hepatic neoplasms (adenoma and carcinoma)
within 6–9 months. Thus, the Albumin-SV40 T antigen
transgenic rat can be used to examine liver cancer develop-
ment and maintenance [20-22].
In this manuscript, we describe a bioinformatics process
where microarray data from the SV40 transgenic rat was
examined for application to the study of HCC in human.
We first used a novel visualization tool to investigate liver
cancer by mapping chromosomal location of differen-
tially expressed genes from the rat model to the chromo-
somal regions of human orthologs. Then, CGMA analysis
was used to relate gene expression bias patterns to cytoge-
netic aberration profiles on human. Lastly, a statistical
approach was used to identify several pathways involved
in human HCC based on the rat microarray. The pathway
analysis reveals that the expected involvement in apopto-
sis, cell cycle, growth and differentiation, genetic stability
and methionine metabolism are important for cancer
development, maintenance and progression. The results
indicate that the gene expression profiles of the transgenic
rat model may be useful in the study of human liver can-
cer.
Methods
Microarray experiment and results
The details of the microarray experimental procedure is
reported elsewhere[21]. Briefly, RNA samples were iso-
lated from the rat liver tissues of six samples, two controls,
two adenomas and two carcinomas. The laser capture
microdissected samples were amplified prior to micro-
array hybridization. An NCI cDNA array (IncyteGem2)
was used that contains 10238 probes representing 9984
unique genes. Gene expression profiles were produced for
all six samples with dye flip, which resulted in a total of
12 arrays.
The log2 ratio-based mean global normalization was first
applied and the normalized ratios of the swapped dye
labels were then averaged. A total of 9150 genes remainedBMC Bioinformatics 2005, 6(Suppl 2):S6
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for further analysis after removing non hybridized genes
due to low intensity. Significantly differentially expressed
genes were determined using an F-test with P < 0 .05.
Data analysis using ArrayTrack
Most analyses were conducted using in-house software,
ArrayTrack http://edkb.fda.gov/webstart/arraytrack/.
ArrayTrack is bioinformatics software, where data man-
agement, analysis and interpretation are fully integrated
[37]. ArrayTrack consists of three components: (1) Micro-
arrayDB for storing microarray data; (2) LIBRARY for data
interpretation that contains many types of functional
information about genes, proteins and pathways; and (3)
TOOL that provides functionality for microarray data
analysis. LIBRARY contains many sub-libraries and data in
these sub-libraries is extracted from different biological
databases in public domain (e.g., NCBI bioinformatics
resources)[38]. In this project, information for orthology
analysis, chromosome-based analysis and pathway analy-
sis was retrieved from LIBRARY. More specifically,
• Gene Orthology Analysis – The human and mouse
orthologs to rat were obtained from the Orthologene
Library in ArrayTrack. The content of the Orthologene
Library are mainly derived from the NCBI HomoloGene
database [4,5]. ArrayTrack allows rapid matching of a
large number of genes across human, mouse and rat for
the gene orthology analysis.
• Chromosome-based analysis – The cytogenetic loca-
tions of genes were exported directly from the Gene
Library of ArrayTrack. A novel visualization tool, the
Chromosome Plot, was developed to study the effect of a
gene expression pattern on liver cancer through identify-
ing the altered cytogenetic regions of each chromosome.
Figure 1 shows a bar chart depiction with the y-axis giving
cytogenetic location along each rat chromosome repre-
sented by 20 vertical bars extending along the x-axis. This
kind of plot has two uses. It depicts rat genes in their
cytogenetic locations on each chromosome using color
coding expression information as red for up-regulation,
green for down and grey for unaffected genes (e.g., Figure
1). Thus, the plot provides for a specific species a compact
visual display of cytogenetic blocks and/or chromosomes
altered. Alternatively, the genes can also be mapped to the
chromosomal location of another species, and color
coded according to the chromosome of the experiment
species. (e.g., Figures 2 for rat mapping to mouse and Fig-
ure 3 for rat mapping to human).
• Pathway analysis – The pathway data was obtained from
the Pathway Library in ArrayTrack. The Pathway Library
contains pathways from both the Kyoto Encyclopedia of
Genes and Genomes (KEGG)[35] and PathArt (Jubilant
Biosys Ltd, Columbia, MD 21045) that can be searched
separately or in combination in ArrayTrack. The Fisher
Exact Test [39] was used to estimate the statistical signifi-
cance of pathway i:
Where N is total number of genes on the chip (i.e., 9150),
m is the number of differential expressed genes identified
using the F-test (i.e., 2223), ni is the number of genes out
of N that belong to pathway i while mi is the number of
genes out of M  differential expressed genes belong to
pathway i. The two-sided Fisher's Exact Test p-value less
than 0.05, suggest that the probability of significant genes
in this pathway is not expected by chance alone.
Comparative Genomic Microarray Analysis (CGMA)
CGMA identifies cytogenetic regions containing unidirec-
tional gene expression biases. The biased regions possibly
indicate chromosomal gains and losses [12]. Of the total
9150 genes, GenBank accession numbers (Refseq in
NCBI) for human orthologs to rodent genes were
obtained for 2925 genes out of 3414 genes with Homolo-
gene ID using the Orthologene Library and Gene Library
in ArrayTrack; ESTs and genes that may be unique to
rodent were excluded. A two-tailed z-statistic was then
computed to test whether chromosomal regions exhibited
gene-expression biases [12]. CGMA was done for each of
two adenoma samples and each of the two carcinoma
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Expressed genes in microarray mapped to the rat cytoge- netic location and chromosome Figure 1
Expressed genes in microarray mapped to the rat 
cytogenetic location and chromosome. The genes 
were obtained from an ANOVA analysis among two con-
trols, two adenomas and two carcinomas samples of the 
transgenic rat. The cytogenetic location of genes is on the y-
axis for each of the 20 rat chromosomes that are displayed 
as separate bars along the x-axis. Red and green areas are the 
significant genes that are up or down regulated, respectively, 
and grey represents those genes not differentially expressed.
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samples using an on line version of software at http://
www.vai.org/vari/supplemental/kyle.furge/development/
clam-0.2.2.pl. Output human CGMA results contained
2728 genes from an input of 2925 Refseq genes. A Z-sta-
tistics of 1.96 corresponds to 95% confidence (that the
expression bias in the chromosome was not due to
chance) and 2.58 corresponds to 99% confidence.
Results
A total of 2223 differentially expressed genes was identi-
fied across three groups of samples (i.e., normal, ade-
noma and carcinoma) based on an F-test. The
differentially expressed genes were first mapped to the rat
chromosome. As depicted in Figure 1, the differentially
expressed genes primarily occurred in several chromo-
somes, indicating that these chromosomes were altered in
rats with neoplasm compared to normal rats. Specifically,
a large number of up-regulated genes mapping in the rat
chromosome 1q is consistent with previous findings of
high amplification in rat liver cancer [22].
To investigate the cross-species extrapolation based on the
results from the transgenic rat, the differentially expressed
genes were first mapped to the orthologous chromosomal
location of the mouse chromosomes. As depicted in Fig-
ure 2, the majority of the differentially expressed genes
from the rat 1q that are known to be important for the rat
liver cancer development appear mainly on the mouse
chromosomes 7, 17, and 19 (displayed as the orange band
in Figure 2). A comparison of rat to human shows that the
differentially expressed genes from the rat 1q appear pri-
marily on human chromosomes 10, 11 and 19 (Figure 3).
The results suggest that the mouse chromosomes (7, 17
and 19) and human chromosomes (10, 11 and 19) might
be important in liver cancer for these species. The findings
are supported by a number of reports [12,23,24].
Table 1 lists the cytogenetic location of the differentially
expressed genes from the rat 1q and location of the orthol-
ogous gene in human and mouse. There are seven groups
of significantly expressed genes (called gene blocks);
genes in each group are consecutive to each other and
across species. The genes in the same blocks could be
coordinately expressed to perform similar transcriptional
programs or physiological processes across species in liver
cancer development and maintenance. For example, the
human gene blocks 10q24-26, 11p15.5, 11q13-15 and
19q13.2 have corresponding blocks on rat 1q, and corre-
sponding blocks on mouse chromosomes 7 and 19. These
blocks are associated with several cancer-related processes
and functions, including apoptosis, M phase, cell commu-
nication and nuclear division as seen in a statistical anal-
ysis based on Gene Ontology (results not shown).
To further confirm the validity of cross-species extrapola-
tion, we investigated chromosomal aberration in human
based on the differentially expressed genes from the rat
model using CGMA. Table 2 summarizes the Z statistics
for each cancer sample from the CGMA analysis. Chromo-
somes exhibiting unidirectional bias with at least 95%
confidence have the table cells with positive value denot-
ing up-regulation or cells with negative vaule denoting
down-regulation. Of 46 chromosomal regions (23 p and
23 q arms), 15 exhibit unidirectional bias in gene expres-
sion. Of the 15 affected chromosomal regions, 14 show
Genes significantly differentially expressed in rat (shown in  Figure 1) mapped to the orthologous genes on chromosome  of mouse Figure 2
Genes significantly differentially expressed in rat 
(shown in Figure 1) mapped to the orthologous 
genes on chromosome of mouse. Different colors 
denote the corresponding rat chromosome number of the 
orthologous genes
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Table 1 : Seven blocks of the significant genes from the rat 1q conservated across rat, mouse and human. The log2-transformed 
expression of average fold change (average over four tumor samples) for each gene is given in column two with direction up or down 
indicated by the sign, where genes with average fold change greater than an arbitrary +1.87 and less than -1.87 are highlighted.
Genes Average Fold
changes Log2
Cytogenetic location (cM) Descriptions
Rat Mouse Human
Tctex1 2.05 1q11 17 3.1 t-complex testis expressed 1
Slc22a1 -0.32 1q11-q12 17 7.34 6q26 solute carrier family 22, member 1
Igf2r 2.53 1q11 17 7.35 6q26 insulin-like growth factor 2 receptor
Psmb1 1.35 1q12 17 8.25 6q27 proteasome (prosome, macropain) subunit, beta type 1
Calm3 3.37 1q22 7 4.0 19q13.2-q13.3 calmodulin 3 carcinoembryonic antigen-related cell adhesion
Ceacam1 -0.40 1q21-q22 7 5.5 19q13.2 molecule 1
Grik5 1.92 1q21 7 6.5 19q13.2 glutamate receptor, ionotropic, kainate 5
Zfp36 1.04 1q21 7 10.2 19q13.1 zinc finger protein 36
Usf2 0.98 1q21 7 11.0 19q13 transcription factor USF2
Sth2 -1.60 1q21.3-q22.1 7 A1 sulfotransferase, hydroxysteroid preferring 2
Rps16 2.55 1q21 7 A3 19q13.1 ribosomal protein S16
Rps19 2.64 1q21 7 A3 19q13.2 ribosomal protein S19
Pafah1b3 1.62 1q21 7 B1 19q13.1 platelet-activating factor acetylhydrolase, isoform 1b, alpha1 subunit
Ech1 0.92 1q21 7 B 19q13.1 enoyl coenzyme A hydratase 1
Atf5 -0.75 1q22 7 B3 19q13.3 activating transcription factor 5
Myd116 -0.86 1q22 7 B3 myeloid differentiation primary response gene 116
Nkg7 -0.88 1q22 7 B3 19q13.41 natural killer cell group 7 sequence
Nucb 0.96 1q22 7 B3 nucleobindin
Pold1 2.06 1q22 7 23.0 19q13.3 DNA polymerase delta, catalytic subunit
Emp3 0.95 1q22 7 24.5 19q13.3 epithelial membrane protein 3
Tead2 2.18 1q22 7 23.0 19q13.3 TEA domain family member 2
Bax 1.65 1q31.2 7 23.0 19q13.3-q13.4 Bcl2-associated X protein
Fzd4 0.55 1q32 7 44.5 11q14.2 frizzled homolog 4 (Drosophila)
Nox4 0.85 1q32 7 D3 11q14.2-q21 NADPH oxidase 4
Rps3 -2.43 1q32 7 E1 11q13.3-q13.5 ribosomal protein S3
Skd3 1.28 1q32 7 E1 11q13.3 suppressor of K+ transport defect 3
Thrsp 0.23 1q32 7 E1 11q13.5 thyroid hormone responsive protein
Ccnd1 -0.43 1q42 7 72.3 11q13 cyclin D1
Ppp1ca 1.92 1q43 7 E3-F2 11q13 protein phosphatase 1, catalytic subunit, alpha isoform
Cfl1 2.83 1q43 19 A 11q13 cofilin 1
Fen1 4.79 1q43 19 A 11q12 Flap structure-specific endonuclease 1
Gstp2 1.43 1q42 19 0.0 glutathione S-transferase, pi 2
Cpt1a -0.42 1q43 19 2.0 11q13.1-q13.2 carnitine palmitoyltransferase 1, liver
Plcb3 1.39 1q43 19 2.5 11q13 phospholipase C, beta 3
Chk 1.06 1q42 19 3.0 11q13.1 choline kinase
Emk(Mark2) 1.63 1q43 19 3.0 11q12-q13 MAP/microtubule affinity-regulating kinase 2 membrane-spanning 
4-domains, subfamily A, member
Ms4a2 -0.83 1q43 19 8.0 11q13 2
Ilk 1.47 1q33 7 E1 11p15.5-p15.4 integrin-linked kinase
Arhg 1.66 1 7 E2 11p15.5-p15.4 Ras homolog gene family, member G
Mrpl17 0.94 1q33 7 E3 11p15.5-p15.4 mitochondrial ribosomal protein L17
Arntl 3.58 1q34 7 52.0 11p15 aryl hydrocarbon receptor nuclear translocator-like
Cd81 -0.60 1q41 7 69.3 11p15.5 CD 81 antigen
Tssc3 2.00 1q41 7 69.5 11p15.5 pleckstrin homology-like domain, family A, member 2
Tnni2 0.97 1q41 7 70.0 11p15.5 troponin 1, type 2
Cdkn1c(p57) 4.28 1q42 7 69.49 11p15.5 cyclin-dependent kinase inhibitor 1C, p57BMC Bioinformatics 2005, 6(Suppl 2):S6
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up-regulation and most of these are associated with ade-
noma. The CGMA results were further compared with
Karyotype results in the Cancer Genome Anatomy Project
(CGAP) in the Mitelman Database [25]. Of 15 affected
chromosomal regions identified from of rat gene expres-
sion data, 10 regions are also reported in CGAP. This is
shown in the last column of Table 2 that lists both the
number of citations and number of patients in CGAP.
We also investigated which pathways in human were sig-
nificantly affected based on the differentially expressed
genes identified in the transgenic rat model. Pathway
analysis is a particular effective way to examine how the
findings in the rat model relate to human in the context of
biological functions. Table 3 summarizes the results of the
pathways analysis. Fifteen pathways were significantly
altered in a Fisher's Exact Test with p < 0.05. They predom-
inately involve cell cycle, cell growth and differentiation.
Most identified pathways are confirmed by a large litera-
ture to be associated with many cancers types [26,27].
Examples are 1) the p53 pathway involved in response to
DNA damage, 2) the Rb pathway involves in the control
of cell cycle, and 3) the transforming growth factor-beta
(TGF-beta) pathway involved in growth inhibition. In
addition, altered methionine metabolism pathway and
regulation of P27 during cell cycle progression are known
to be critical for cancer progression [28].
Discussion
This study investigates the implications of using micro-
array results from the albumin-SV40 transgenic rat for the
study of human liver cancer. We demonstrated the impor-
tance of bioinformatics to interpret microarray data for
the cross-species comparisons. Specifically, two in-house
bioinformatics tools are of importance for the analysis,
the Chromosome Plot and ArrayTrack. The Chromosome
Plot not only provides a visual presentation of the gene
expression pattern at the level of gene order across chro-
mosomes (e.g., Figure 1), but also can be used to map
chromosome and cytogenetic location of differentially
expressed genes from one species to another (e.g., Figures
2 and 3). ArrayTrack software that integrates data from
public repositories was used to identify the cross-species
orthologous genes, their chromosomal locations and,
most importantly, the pathways that may be related to
liver cancer. In addition, CGMA analysis was performed to
investigate the variability of the multiple chromosome
aberration patterns based on gene expression data, which
is compared with the results presented in CGAP.
Implications of orthologs and chromosome-based analysis
The recently completed sequencing of the rat genome pro-
vides a basis for future research to elucidate how differ-
ences and commonalities affect the ability of rat models to
predict human disease. The rat genome project reported
that almost all human genes known to be associated with
disease have orthologous genes in the rat genome, and
that human, mouse and rat genomes are approximately
90% orthologous [1]. We also analyzed orthologous
genes between human, rat and mouse among the 9150
genes on the chip using ArrayTrack. The chip was found in
Orthologene Library in ArrayTrack to contain 3414
human, 3365 mouse and 1950 rat genes, with the rest of
genes being either EST tags or Riken genes (about 1500).
The results showed that 92% of human genes are orthol-
ogous to either rat or mouse.
Although a large number of genes was identified to be dif-
ferentially expressed from the rat model, some of these
genes may result from the cancer rather than causally
Coro1a 1.10 1q36 7 62.5 16p12.1 coronin, actin binding protein 1A
Mapk3 1.80 1q36 7 61.0 16p12-p11.2 protein kinase, mitogen activated 3 
(extracellular-signal-regulated kinase 1, ERK1)
Maz 1.97 7 F3 16p11.2 MYC-associated zinc finger protein 
(purine-binding transcription factor)
Ppp4c 1.23 1q36 7 F3 16p12-16p11 protein phosphatase 4 (formerly X), catalytic subunit
Umod -0.88 1q36-q37 7 55.0 16p13.11 uromodulin
Fgfr2 -0.68 1q37 7 63.0 10q26 fibroblast growth factor receptor 2
Cyp2e1 -0.08 1q41-42 7 68 10q24.3 cytochrome P450, family 2, subfamily e, polypeptide 1
Echs1 -0.38 1q41 7 F4 10q26.2-q26.3 enoyl Coenzyme A hydratase, short chain 1
Oat -0.12 1q41 7 63.0 10q26 ornithine aminotransferase
Scd1 0.40 1q54 19 43.0 stearoyl-Coenzyme A desaturase 1
Pitx3 0.95 1q54 19 46.5 10q25 paired-like homeodomain transcription factor 3
Add3 1.81 1q55 19 47.0 10q24.2-q24.3 adducin 3, gamma
Cspg6 2.73 1q55 19 D2 10q25 chondroitin sulfate proteoglycan 6
Cyp17 -0.64 1q55 19 46.0 10q24.3 cytochrome P450, subfamily 17
Pnliprp1 -0.87 1q55 19 29.0 10q26.12 pancreatic lipase related protein 1
Pdcd4 1.01 1q55 19 20.0 10q24 programmed cell death 4
Table 1 (Continued): Seven blocks of the significant genes from the rat 1q conservated across rat, mouse and human. The log2-
transformed expression of average fold change (average over four tumor samples) for each gene is given in column two with direction 
up or down indicated by the sign, where genes with average fold change greater than an arbitrary +1.87 and less than -1.87 are BMC Bioinformatics 2005, 6(Suppl 2):S6
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related. In addition, the function of a specific gene and its
involvement in cancer might not be conserved across spe-
cies. Thus, as important as structural and functional hom-
ology of specific genes is, the conservation of function of
blocks of genes is likely to be more important in cross-spe-
cies comparison. We found seven distinct blocks of signif-
icantly differentially expressed genes within different
cytogenetic regions of the rat 1q with homologous chro-
mosomal segments in human and mouse (Table 1). How-
ever, human, mouse and rat have very different
chromosomal arrangements. The genes in these blocks
appear consecutively in contiguous cytogenetic regions,
irrespective of species and chromosomal location. This
finding is not surprising considering the close evolution-
Table 2: Summary of the Z statistics for human chromosomes for each test sample from the CGMA analysis. A Z-statistics of 1.96 
corresponds to α = 0.05, or 95% confidence that the expression bias in the chromosome was not due to chance. A Z-statistic of 2.58 
corresponds to 99% confidence. Chromosomes exhibiting unidirectional bias with at least 95% confidence have positive sign denoting 
up-regulation or negative sign for denoting down-regulation.
Chromosome Region Adenoma sample
1
Adenoma sample
2
Carcinoma sample 
1
Carcinoma sample 
2
Karyotype results in 
CGAP # Citations (# 
Patients)
1.p 2.06 2.67 -1 1.5 1 (1)
7.p 0.82 2.45 -0.58 1.34 8 (34)
9.p 1.41 1.41 -2.24 -2 5 (23)
11.p 1 2.53 0.82 0.82 4 (10)
11.q 0.63 2.29 0 . 2 304  ( 1 0 )
12.p 1.63 2.24 0- 1 2  ( 4 )
12.q 2.13 2.2 1.96 1.94 2 (4)
14.- 1.73 2.84 2.24 2.56
16.- 2.84 3.13 00 1  ( 1 )
17.q 0.65 2 0.5 0 1 (6)
19.p 2.83 3.15 2.84 1.67
19.q 2.2 2.83 2.83 1.7
20.q 3.27 0.71 1.6 1.81 5 (20)
21.- 2.53 3 0 1.67
22.- 1.94 2.67 0.71 1.63
Table 3: Pathway analysis of 2223 significant genes using a Fisher's Exact Test identified the listed pathways (p < 0.05) that might be 
related to human liver cancer.
Pathways The number of significant genes found in a pathway divided by 
the genes from the chip found in the same pathway
P value
Apoptosis
TGF Beta Induced apoptosis 18/35 0.00055
Cell cycle
P53 signaling pathway 11/21 0.0079
Regulation of P27 during cell cycle progression 6/8 0.0036
Influence of Ras and Rho Protein on G1 to S transition 9/12 0.00031
ECM and Integrin mediated signaling pathway 6/10 0.017
Rb signaling pathway 10/13 0.0001
Cyclin mediated Pathway 13/19 0.000062
G1-S checkpoint 15/21 0.0000072
Growth and differentiation
Insulin signaling pathway 8/16 0.035
TGF beta signaling pathway 7/13 0.021
Amino Acid/Metabolic pathway
Methionine Metabolism 4/5 0.014
Other Signaling pathways
PKC-mediated pathway 8/13 0.0047
Heregulin signaling pathway 14/34 0.027
AR Mediated Signaling Pathway 9/20 0.038
Apigenin Signaling Pathway 6/9 0.0085BMC Bioinformatics 2005, 6(Suppl 2):S6
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ary distance between the species where 278 orthologous
segments are reported to be shared between human and
rat, and 280 segments are reported to be shared between
human and mouse [1].
It is proposed that these seven blocks of genes may be of
significance for liver cancer development, maintenance
and progression across human, rat, and mouse. For exam-
ple, genes in the blocks may be coordinately expressed to
share transcription programs or to respond to the
genomic instability observed in liver cancer. Several genes
in Table 1 show large fold changes, and are implicated in
cancer development and maintenance. For example,
Rps16, Rps19 and Rps3 code for ribosomal proteins, and
their altered expression has been associated with liver and
other tumors [29,30]. Insulin-like growth factor2 receptor
(Igf2r) is mutated in many human HCC tumors and the
gene's haploid insufficiency has been suggested as an early
event in human hepatocarcinogenesis [31]. Cyclin D1
(Ccnd1) and cyclin-dependent kinase inhibitor 1C
(Cdkn1c = p57) are critical for the cell cycle, including G1
progression and G1/S transition. Cyclin D1 has been
shown to be amplified in 10 to 20% of HCCs.
Implication of CGMA analysis
Chromosomal aberrations are common in cancers, partic-
ularly in advanced stages. CGH has been employed to
determine gross DNA gains and losses at chromosomal
and sub-chromosomal levels [10]. CGH, however, is time-
consuming, and lacks the resolution and sensitivity to
detect changes at the gene level; for example, CGH is una-
ble to detect copy number changes within narrow regions
of chromosomes (alternation of <1 Mb). It fails to identify
putative tumor-suppressor genes or oncogenes [32]. These
limitations might be overcome by using CGMA [12].
CGMA identifies cytogenetic regions containing unidirec-
tional gene expression biases. Such region-dependent
expression change may be the result of allelic imbalances
commonly found in liver and other cancers. Evidence
shows that DNA copy number alterations (deletion, low,
mid and higher-level amplification) with an average 2-
fold change in DNA copy number corresponds about a
1.5-fold change in mRNA level [33]. Therefore, CGMA
based on microarray data measuring mRNA level could be
related to DNA level.
Using CGMA, we identified 15 out of 46 (23 p and 23 q
arms) human chromosomal regions that could be
involved in liver cancer development, maintenance and
progression. These chromosomal aberrations are consist-
ent with the CGAP report for 10 out of 15 chromosome
regions by karyotypes (Table 2). Although CGAP database
(Table 2) cites no evidence of involvement of chromo-
some 19 in human liver cancer, we found that genes in
both chromosome 19q and 19p are significantly down-
regulated for three out of four tumor samples. In addition,
there is also a block of genes in 19q that corresponds to rat
1q (Table 1) while a large number of differentially
expressed genes also occurs in 19p using the Chromo-
some Plot (Figure is not shown). Analysis of both human
19p and q suggests the possible relevance of the chromo-
some in human liver cancer. The genes significantly
altered in rat micorarray corresponding to human 19p13
are JunB, Rab8a (Mel), Tnfsf9 and Dnmt1. Further inves-
tigation is required to confirm their relevance to human
HCC. Comparing with the findings by Crawley et al [12],
we predicted chromosomal gains for five (12q, 16, 17q,
19p and 20q) out of eight of those reported by Crawley
who carried out CGMA with human HCC gene expression
arrays. Both our analysis and that of Crawley's suggest the
importance of 19p in the human liver cancer, a region of
aberration not previously discovered with CGH analysis.
These results indicate human 19p as a region of aberration
not previously discovered with CGH analysis.
Implications of pathway analysis
Pathways are the best vehicle for interpretation of biolog-
ical functions of genes. An important goal of modern biol-
ogy is to identify the interaction and regulatory networks
among biological molecules. A logical approach is to ana-
lyze the gene expression changes in the context of known
biological pathways [34,35]. A number of human path-
ways were found to be significantly altered using the
Fisher's Exact Test by comparing the number of genes with
altered expression in a pathway to the number of genes on
the chip in the same pathway.
We inferred which pathways are involved in human liver
cancer from the differentially expressed genes in the trans-
genic rat liver cancer model. It is important to point out
that the statistically significant pathways identified in this
process were solely based on the analysis of microarray
data together with the Orthologene and Pathway Libraries
in ArrayTrack, and thus required no a priori knowledge
regarding cancer genes and the pathways that they con-
trol. The results of the pathway analysis given in Table 3
include those involved in apoptosis, cell cycle, cell growth
and differentiation and others that are significant in liver
cancer.
Most of the altered pathways are involved in cell cycle reg-
ulation. In cancer, disruption of cell cycle regulation is
accomplished by coordinating the activity of cyclin-
dependent kinases, checkpoint controls, and DNA repair
pathways, which, when perturbed lead to uncontrolled
cell growth [27]. Not surprisingly, our studies support that
P53 and Rb signaling pathways as well as cyclin mediated
pathway including G1-S checkpoints are altered. Both p53
and Rb are tumor-suppressor genes, and their products are
transcription factors that respond to a variety of stress sig-BMC Bioinformatics 2005, 6(Suppl 2):S6
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nals and are often associated with the progression of neo-
plastic diseases. The transgenic model implies that both
P53 and Rb signaling pathways could be disrupted in the
human liver cancer. Without P53 and Rb, cell cycle arrest
and/or programmed cell death (apoptosis) are inhibited,
leading to accumulation of mutations and genetic insta-
bility. Since P53 is deactivated in this transgenic model,
we also observed that the pathway that influences Ras and
Rho proteins during G1 to S transition is altered. Ras is a
proto-oncogene that is involved in multiple signal trans-
duction pathways transmitting pro-proliferative signals to
the nucleus, while Rho proteins are members of the
extended Ras family that modulate gene expression, cell
cycle progression, and cell proliferation and survival.
Categoies of altered pathways are associated with growth
and differentiation. Genes in the ECM (extracellular
matrix) and Integrin mediated signaling pathway have
been reported to be over-expressed in human HCC,
though the mechanism is not fully understood [36]. In
addition, an excess of TGF-beta is thought to overwhelm
the cell in two ways. First, it promotes the overgrowth of
blood vessels. Second, excess TGF-beta suppresses T cells
and other components of the immune system that would
normally attack aberrant cells.
The human-relevant liver cancer pathways based on SV 40
transgenic rat liver model are confirmed by reports on
human liver cancer models. Therefore, the pathway anal-
ysis using Fisher's Exact Test is novel and efficient.
Conclusion
We presented several bioinformatics approaches to
extrapolate microarray data involving rat liver cancer to
the human. Microarray has been widely used in many
fields of medical and biological research. The current chal-
lenge of bioinformatics of microarray is no longer to iden-
tify a list of differentially expressed genes, but to develop
effective bioinformatics processes and tools for data inter-
pretation and knowledge discovery. In this study, we first
developed a Chromosome Plot that provides a compact
visual summary of gene expression data at the level of
chromosomal location for identification of altered chro-
mosomal regions. This tool facilitates cross-species com-
parison. The information available in ArrayTrack on gene
ontology, gene orthologs and gene pathways was then
used to interpret the microarray data. Finally, the CGMA
bioinformatics tool was uesd to infer HCC chromosomal
aberrations in the human based on microarray data from
rat. The important lesson of this study is how to limit the
information using bioinformatics resources and statistical
means to present an unbiased (or statistical) view to inter-
pret microarray results with respect to genes, pathways,
chromosomes and functions. Based on a thorough bioin-
formatics analysis, we found that the albumin-SV40 trans-
genic rat is a useful animal model for prediction of human
liver cancer.
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